Jeffrey Yap

Jeffrey Yap, PhD

Languages spoken: English

Academic Information

Departments Primary - Radiology & Imaging Sciences

Lab

Jeffrey Yap, PhD, is a research professor in the Department of Radiology and Imaging Sciences at the University of Utah. He is also the Director of the Center for Quantitative Cancer Imaging and Theranostics and a member of the Experimental Therapeutics Program at the Huntsman Cancer Institute. Dr. Yap's research interest is in the use of quantitative multimodality imaging to develop and evaluate novel cancer therapy in murine tumor models and cancer clinical trials. Dr. Yap received a Bachelor's of Science in Physics at the University of Dallas and a PhD in Medical Physics at the University of Chicago.

Education History

Undergraduate University of Dallas
 BS
Doctoral Training University of Chicago, Departments of Radiology and Radiation & Cellular Oncology
 PhD

Selected Publications

Journal Article

  1. Otero HJ, Yap JT, Patak MA, Erturk SM, Israel DA, Johnston CJ, Sakellis C, Rybicki FJ, Van den Abbeele AD, Ros PR (2009). Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial. AJR Am J Roentgenol, 193(2), 326-32. (Read full article)
  2. Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Janne PA, Johnson BE, Van den Abbeele AD (2010). New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol, 195(3), W221-8. (Read full article)
  3. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI (2012). Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood, 119(20), 4597-607. (Read full article)
  4. Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, Harris A (2003). Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. British journal of cancer, 89(2), 262-7. (Read full article)
  5. Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George (2016). Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Annals of oncology, 27(9), 1794-9. (Read full article)
  6. Karsy M, Gillespie DL, Horn KP, Burrell LD, Yap JT, Jensen R (2018). Correlation of Glioma Proliferation and Hypoxia by Luciferase, Magnetic Resonance, and Positron Emission Tomography Imaging. Methods in molecular biology (Clifton, N.J.), 1742, 301-320. (Read full article)
  7. Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri T (2011). Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. European urology, 59(5), 856-62. (Read full article)
  8. Aristophanous M, Yap JT, Killoran JH, Chen AB, Berbeco R (2011). Four-dimensional positron emission tomography: implications for dose painting of high-uptake regions. International journal of radiation oncology, biology, physics, 80(3), 900-8. (Read full article)
  9. Aristophanous M, Berbeco RI, Killoran JH, Yap JT, Sher DJ, Allen AM, Larson E, Chen A (2012). Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning. International journal of radiation oncology, biology, physics, 82(1), e99-105. (Read full article)
  10. Balter JM, Haffty BG, Dunnick NR, Siegel EL, Balter J, Dunnick NR, Haffty B, Siegel E, Palta J, Hahn S, Cao Y, Bentzen S, Van den Abbeele A, Luker G, Michalski J, Galvin J, Khoo V, Alber M, Low D, Mageras G, Atcher R, Yap J, Jeraj R, Jackson E, Wahl R, Deye J, Clarke L, Vikram B, Stone H, Wong R, Croft B, Farahani K, Kelloff G, Shankar (2011). Imaging opportunities in radiation oncology. International journal of radiation oncology, biology, physics, 79(2), 342-7.
  11. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price P (2003). Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. Journal of clinical oncology, 21(15), 2823-30. (Read full article)
  12. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan M (2009). Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. Journal of clinical oncology, 27(19), 3154-60. (Read full article)
  13. George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri G (2012). Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. Journal of clinical oncology, 30(19), 2401-7. (Read full article)
  14. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher D (2013). Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. Journal of clinical oncology, 31(26), 3182-90. (Read full article)
  15. Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga C (2014). Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of clinical oncology, 32(12), 1202-9. (Read full article)
  16. Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele A (2015). Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Journal of clinical oncology, 33(24), 2623-31. (Read full article)
  17. O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap J (2016). Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. Journal of neuro-oncology, 130(3), 495-503. (Read full article)
  18. Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O, Camici P (1999). Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. Journal of nuclear medicine, 40(11), 1848-56. (Read full article)
  19. Gunn RN, Ranicar A, Yap JT, Wells P, Osman S, Jones T, Cunningham V (2000). On-line measurement of exhaled [11C]CO2 during PET. Journal of nuclear medicine, 41(4), 605-11. (Read full article)
  20. Gunn RN, Yap JT, Wells P, Osman S, Price P, Jones T, Cunningham V (2000). A general method to correct PET data for tissue metabolites using a dual-scan approach. Journal of nuclear medicine, 41(4), 706-11. (Read full article)
  21. Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel B (2012). ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. Journal of nuclear medicine, 53(4), 567-74. (Read full article)
  22. Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, Perlman ES, Kinahan PE, Christian PE, Hoekstra OS, Dorfman G (2015). Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials. Journal of nuclear medicine, 56(6), 955-61. (Read full article)
  23. Wall JS, Kennel SJ, Paulus M, Gregor J, Richey T, Avenell J, Yap J, Townsend D, Weiss DT, Solomon (2006). Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. Journal of nuclear medicine, 47(12), 2016-24. (Read full article)
  24. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D, National Cancer Institute (2006). Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. Journal of nuclear medicine, 47(6), 1059-66. (Read full article)
  25. Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF Jr, Syngal S, Garber J (2008). F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA, 299(11), 1315-9. (Read full article)
  26. Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, Jones T, Price PM, Aboagye E (2000). Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet (London, England), 355(9221), 2125-31. (Read full article)
  27. Saffari H,Peterson KA, Leiferman KM, Stabin MG, Krstyen JJ, Clayton FC, Pease LF III,Yap JT,Hoffman JM, Gleich G Oral Administration of 99mTechnetium-Labelled Heparin in Eosinophilic Esophagitis. Mayo Clinic proceedings,
  28. Saffari H, Peterson KA, Leiferman KM, Stabin MG, Krstyen JJ, Clayton FC, Pease LF 3rd, Yap JT, Hoffman JM, Gleich G (2020). Oral Administration of 99mTechnetium-Labeled Heparin in Eosinophilic Esophagitis. Mayo Clinic proceedings, 95(3), 449-458. (Read full article)
  29. Aristophanous M, Yong Y, Yap JT, Killoran JH, Allen AM, Berbeco RI, Chen A (2012). Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans. Radiotherapy and oncology, 102(3), 377-82. (Read full article)
  30. Guo M, Yap JT, Van den Abbeele AD, Lin NU, Schwartzman (2014). Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology. Stat, 3(1), 172-186. (Read full article)
  31. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon (2019). Protective autophagy elicited by RAF'MEK'ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature medicine, 25(4), 620-627. (Read full article)
  32. Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson K (2008). Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clinical cancer research, 14(8), 2387-95. (Read full article)
  33. Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald T (2009). Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology. Clinical cancer research, 15(6), 1891-7.
  34. von Mehren M, George S, Heinrich MC, Schuetze SM, Yap JT, Yu JQ, Abbott A, Litwin S, Crowley J, Belinsky M, Janeway KA, Hornick JL, Flieder DB, Chugh R, Rink L, Van den Abbeele A (2020). Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. Clinical cancer research, 26(8), 1837-1845. (Read full article)
  35. Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson B (2011). CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Academic radiology, 18(1), 54-62. (Read full article)
  36. Yap JT, Carney JP, Hall NC, Townsend D (2004). Image-guided cancer therapy using PET/CT. Cancer journal (Sudbury, Mass.), 10(4), 221-33. (Read full article)
  37. Laforest R, Longford D, Siegel S, Newport DF, Yap (2007). Performance Evaluation of the microPET®¿FOCUS-F120. IEEE transactions on nuclear science, 54(1), 42-49.
  38. Barrott JJ, Zhu JF, Smith-Fry K, Susko AM, Nollner D, Burrell LD, Pozner A, Capecchi MR, Yap JT, Cannon-Albright LA, Deng X, Jones K (2017). The Influential Role of BCL2 Family Members in Synovial Sarcomagenesis. Molecular cancer research, 15(12), 1733-1740. (Read full article)
  39. Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele A (2014). Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer imaging, 14, 30. (Read full article)
  40. Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman J (2015). FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer imaging, 15(1), 15. (Read full article)
  41. Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin M (2015). A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clinical genitourinary cancer, 13(2), 113-23. (Read full article)
  42. Mihalopoulos NL, Yap JT, Beardmore B, Holubkov R, Nanjee MN, Hoffman J (2020). Cold-Activated Brown Adipose Tissue is Associated with Less Cardiometabolic Dysfunction in Young Adults with Obesity. Obesity (Silver Spring, Md.), 28(5), 916-923. (Read full article)
  43. Carney JPJ, Yap JT, Townsend D (2004). PET count rate performance and CT image quality of a 16-slice LSO PET/CT for clinical whole-body imaging. Radiation physics and chemistry (Oxford, England, (71), 963-965.
  44. Wang LM, Wu Q, Kirk RA, Horn KP, Ebada Salem AH, Hoffman JM, Yap JT, Sonnen JA, Towner RA, Bozza FA, Rodrigues RS, Morton K (2018). Lipopolysaccharide endotoxemia induces amyloid-ß and p-tau formation in the rat brain. American journal of nuclear medicine and molecular imaging, 8(2), 86-99. (Read full article)
  45. Abbott D, O'Brien S, Farnham JM, Young EL, Yap J, Jones K, Lessnick SL, Randall RL, Schiffman JD, Cannon-Albright L (2019). Increased risk for other cancers in individuals with Ewing sarcoma and their relatives. Cancer medicine, 8(18), 7924-7930. (Read full article)
  46. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC Jr, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott (2014). Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer immunology research, 2(7), 632-42. (Read full article)
  47. Qin L, Schwartzman A, McCall K, Kachouie NN, Yap J (2017). Method for detecting voxelwise changes in fluorodeoxyglucose-positron emission tomography brain images via background adjustment in cancer clinical trials. Journal of medical imaging (Bellingham, Wash.), 4(2), 024006. (Read full article)
  48. Swami U, Yap JT, Agarwal (2020). Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer. JAMA oncology, 6(2), 225-226. (Read full article)
  49. Mihalopoulos NL, Yap JT, Holubkov R, Balch A, Hoffman J Metabolically Active Brown Adipose Tissue Lowers Metabolic Dysfunction Among Obese and Morbidly Obese Young Adults.
  50. Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal R, Porretta J, Brownson KE, Matsen CB, Vaklavas C, Ward JH, Wei M, Buys SS, Chittoria N, Yakish ED, Archibald ZG, Burrell LD, Butterfield RI, Yap J (2023). Prospective Pilot Study of (18)F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas. AJR. American journal of roentgenology, 221(2), 228-239. (Read full article)
  51. Silvis MR, Silva D, Rohweder R, Schuman S, Gudipaty S, Truong A, Yap J, Affolter K, McMahon M, Kinsey (2023). MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. The Journal of experimental medicine, 220(3), (Read full article)
  52. Coletta AM, Lee H, Puri S, Culleton S, Covington MF, Yap JT, Maslana KE, Haaland B, Akerley (2025). The Association Between Body Composition, Overall Survival, Treatment Decisions, and Patient-Reported Outcomes in Metastatic Non-Small-Cell Lung Cancer. Cancer medicine, 14(1), e70534. (Read full article)
  53. Diehl G, Archibald ZG, Gingrich K, Ballance AT, Buckway B, Shumaker-Parry JS, Yap JT, Zharov I, Mastren (2025). Theranostic nanoparticles: Investigation of superparamagnetic iron oxide nanoparticles intrinsically labeled with Zirconium-89 and Actinium-225. Nuclear medicine and biology, 146-147, 109045. (Read full article)
  54. Covington MF, Salmon S, Kozlov A, Archibald Z, Butterfield R, Stolk S, Mitchell S, Boucher K, Rosenthal R, Porretta J, Brownson KE, Matsen C, Wei M, Buys S, Vaklavas C, Chittoria N, Buckway B, Meite A, Yap (2026). Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT. Clinical breast cancer, 26(1), 36-46. (Read full article)

Review

  1. Townsend DW, Carney JP, Yap JT, Hall N (2004). PET/CT today and tomorrow. Journal of nuclear medicine, 45 Suppl 1, 4S-14S. (Read full article)
  2. Karsy M, Gillespie DL, Horn K, Harper J, Ruesch M, Yap JT, Jensen R (2018). MRI of Hypoxia in Primary Central Nervous System Tumors: Part II. Contemporary neurosurgery, 40(13), 1-8.

Book Chapter

  1. Yap JT, Townsend DW, Hall N (2005). Chapter 8: PET/CT in IMRT Planning. 115-130.

Other

  1. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon (2019). Publisher Correction: Protective autophagy elicited by RAF'MEK'ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature medicine, 25(5), 861. (Read full article)
  2. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon (2025). Author Correction: Protective autophagy elicited by RAF'MEK'ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature medicine, 31(6), 2069. (Read full article)

News & Podcasts

Huntsman Cancer Institute News